Biomarkers for Hepatocellular Cancer

Overview

Journal World J Hepatol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2020 Oct 9

PMID 33033565

Citations 19

Authors

Gurjot Singh

Eric M Yoshida

Sahaj Rathi

Vladimir Marquez

Peter Kim

Siegfried R Erb

Baljinder S Salh

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide. If diagnosed early, curative treatment options such as surgical resection, loco-regional therapies, and liver transplantation are available to patients, increasing their chances of survival and improving their quality of life. Unfortunately, most patients are diagnosed with late stage HCC where only palliative treatment is available. Therefore, biomarkers which could detect HCC early with a high degree of sensitivity and specificity, may play a crucial role in the diagnosis and management of the disease. This review will aim to provide an overview of the different biomarkers of HCC comprising those used in the diagnosis of HCC in at risk populations, as well as others with potential for prognosis, risk predisposition and prediction of response to therapeutic intervention.

Citing Articles

Biomarker in Hepatocellular Carcinoma.

Basthi Mohan P, Lochan R, Shetty S Indian J Surg Oncol. 2024; 15(Suppl 2):261-268.

PMID: 38817995 PMC: 11133295. DOI: 10.1007/s13193-023-01858-x.

Mechanistically based blood proteomic markers in the TGF-β pathway stratify risk of hepatocellular cancer in patients with cirrhosis.

Xiang X, Bhowmick K, Shetty K, Ohshiro K, Yang X, Wong L Genes Cancer. 2024; 15():1-14.

PMID: 38323119 PMC: 10843195. DOI: 10.18632/genesandcancer.234.

Chinese expert consensus statement on the clinical application of AFP/AFP-L3%/DCP using GALAD and GALAD-like algorithm in HCC.

Huang C, Xiao X, Zhou L, Chen F, Wang J, Hu X J Clin Lab Anal. 2023; 37(23-24):e24990.

PMID: 38063322 PMC: 10756949. DOI: 10.1002/jcla.24990.

Development and clinical validation of a novel algorithmic score (GAAD) for detecting HCC in prospective cohort studies.

Piratvisuth T, Hou J, Tanwandee T, Berg T, Vogel A, Trojan J Hepatol Commun. 2023; 7(11).

PMID: 37938100 PMC: 10635602. DOI: 10.1097/HC9.0000000000000317.

The Current Status of the Liver Liquid Biopsy in MASH Related HCC: Overview and Future Directions.

Ugonabo O, Udoh U, Rajan P, Reeves H, Arcand C, Nakafuku Y Biomolecules. 2023; 13(9).

PMID: 37759769 PMC: 10526956. DOI: 10.3390/biom13091369.

References

Dick M, Versmold B, Engel C, Meindl A, Arnold N, Varon-Mateeva R . Association of death receptor 4 variant (683A > C) with ovarian cancer risk in BRCA1 mutation carriers. Int J Cancer. 2011; 130(6):1314-8. DOI: 10.1002/ijc.26134. View

El-Serag H, Rudolph K . Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007; 132(7):2557-76. DOI: 10.1053/j.gastro.2007.04.061. View

Zhang B, Yang B, Tang Z . Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004; 130(7):417-22. DOI: 10.1007/s00432-004-0552-0. View

Llovet J, Fuster J, Bruix J . Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999; 30(6):1434-40. DOI: 10.1002/hep.510300629. View

Stros M . HMGB proteins: interactions with DNA and chromatin. Biochim Biophys Acta. 2010; 1799(1-2):101-13. DOI: 10.1016/j.bbagrm.2009.09.008. View

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

Yang J, Addissie B, Mara K, Harmsen W, Dai J, Zhang N . GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiol Biomarkers Prev. 2018; 28(3):531-538. PMC: 6401221. DOI: 10.1158/1055-9965.EPI-18-0281. View

Zhou J, Yu L, Gao X, Hu J, Wang J, Dai Z . Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol. 2011; 29(36):4781-8. DOI: 10.1200/JCO.2011.38.2697. View

Tsai W, Hsu S, Hsu C, Lai T, Chen S, Shen R . MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest. 2012; 122(8):2884-97. PMC: 3408747. DOI: 10.1172/JCI63455. View

10.

Zhang H, Bradley A . Mice deficient for BMP2 are nonviable and have defects in amnion/chorion and cardiac development. Development. 1996; 122(10):2977-86. DOI: 10.1242/dev.122.10.2977. View

11.

Singal A, Pillai A, Tiro J . Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med. 2014; 11(4):e1001624. PMC: 3972088. DOI: 10.1371/journal.pmed.1001624. View

12.

Li T, Xie J, Shen C, Cheng D, Shi Y, Wu Z . Upregulation of long noncoding RNA ZEB1-AS1 promotes tumor metastasis and predicts poor prognosis in hepatocellular carcinoma. Oncogene. 2015; 35(12):1575-84. DOI: 10.1038/onc.2015.223. View

13.

Schnekenburger M, Florean C, Dicato M, Diederich M . Epigenetic alterations as a universal feature of cancer hallmarks and a promising target for personalized treatments. Curr Top Med Chem. 2015; 16(7):745-76. DOI: 10.2174/1568026615666150825141330. View

14.

Luo P, Yin P, Hua R, Tan Y, Li Z, Qiu G . A Large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma. Hepatology. 2017; 67(2):662-675. PMC: 6680350. DOI: 10.1002/hep.29561. View

15.

Ai N, Liu W, Li Z, Ji H, Li B, Yang G . High expression of GP73 in primary hepatocellular carcinoma and its function in the assessment of transcatheter arterial chemoembolization. Oncol Lett. 2017; 14(4):3953-3958. PMC: 5604171. DOI: 10.3892/ol.2017.6697. View

16.

Chen Y, Li S, Li W, Yang R, Zhang X, Ye Y . Circulating tumor cells undergoing EMT are poorly correlated with clinical stages or predictive of recurrence in hepatocellular carcinoma. Sci Rep. 2019; 9(1):7084. PMC: 6506548. DOI: 10.1038/s41598-019-43572-1. View

17.

Marrero J, Su G, Wei W, Emick D, Conjeevaram H, Fontana R . Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology. 2003; 37(5):1114-21. DOI: 10.1053/jhep.2003.50195. View

18.

DiStefano J, Davis B . Diagnostic and Prognostic Potential of AKR1B10 in Human Hepatocellular Carcinoma. Cancers (Basel). 2019; 11(4). PMC: 6521254. DOI: 10.3390/cancers11040486. View

19.

Capurro M, Wanless I, Sherman M, Deboer G, Shi W, Miyoshi E . Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology. 2003; 125(1):89-97. DOI: 10.1016/s0016-5085(03)00689-9. View

20.

Li J, Gao J, DU J, Wei L . Prognostic and clinicopathological significance of glypican-3 overexpression in hepatocellular carcinoma: a meta-analysis. World J Gastroenterol. 2014; 20(20):6336-44. PMC: 4033473. DOI: 10.3748/wjg.v20.i20.6336. View